Edition:
United States

Progenics Pharmaceuticals Inc (PGNX.OQ)

PGNX.OQ on NASDAQ Stock Exchange Global Select Market

7.02USD
4:00pm EDT
Change (% chg)

$-0.15 (-2.09%)
Prev Close
$7.17
Open
$7.13
Day's High
$7.21
Day's Low
$6.87
Volume
285,057
Avg. Vol
344,874
52-wk High
$8.63
52-wk Low
$4.61

Chart for

About

Progenics Pharmaceuticals, Inc. is engaged in developing medicines and other products for targeting and treating cancer. The Company's pipeline includes therapeutic agents designed to target cancer (AZEDRA and 1095); prostate specific membrane antigen (PSMA)-targeted imaging agents for prostate cancer (1404 and PyL), and imaging... (more)

Overall

Beta: 3.54
Market Cap(Mil.): $515.08
Shares Outstanding(Mil.): 70.27
Dividend: --
Yield (%): --

Financials

  PGNX.OQ Industry Sector
P/E (TTM): -- 84.02 32.74
EPS (TTM): -0.06 -- --
ROI: -3.04 1.58 14.38
ROE: -5.26 2.41 16.07

BRIEF-Progenics Says FDA Will Extend Review Of NDA For Azedra By Three Months

* PROGENICS PHARMACEUTICALS ANNOUNCES THREE-MONTH EXTENSION OF PDUFA DATE FOR AZEDRA (IOBENGUANE I 131)

Mar 22 2018

BRIEF-Progenics Pharmaceuticals Completes Enrollment In Phase 3 Study Of Psma-Targeted Imaging Agent 1404

* PROGENICS PHARMACEUTICALS COMPLETES ENROLLMENT IN PHASE 3 STUDY OF PSMA-TARGETED IMAGING AGENT 1404 Source text for Eikon: Further company coverage:

Jan 02 2018

BRIEF-Progenics Pharmaceuticals Announces FDA Acceptance Of Marketing Application For Azedra In Pheochromocytoma And Paraganglioma

* PROGENICS PHARMACEUTICALS ANNOUNCES FDA ACCEPTANCE OF NEW DRUG APPLICATION FOR AZEDRA® (IOBENGUANE I 131) IN PHEOCHROMOCYTOMA AND PARAGANGLIOMA

Dec 29 2017

BRIEF-Progenics Pharmaceuticals Q3 loss per share $0.22

* Progenics Pharmaceuticals announces third quarter 2017 financial results and business update

Nov 02 2017

Earnings vs. Estimates